Drugs / PQ203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07190469 | Sep 2025 → Dec 2028 expected | triple-negative breast carcinoma | ProteinQure Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-08-07 | ProteinQure Inc. | Regulatory ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation proteinqure.com ↗
The FDA has also granted PQ203 Fast Track designation for patients with triple negative breast cancer, recognizing the therapy’s potential to address a serious unmet medical need. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-17 | ProteinQure Inc. | ProteinQure Announces First Patient Dosed in Phase I Clinical Trial of PQ203 in Advanced Metastatic Cancer proteinqure.com ↗ |
| 2025-08-07 | ProteinQure Inc. | ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation proteinqure.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PQ203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07190469 ↗ |
| Modality | Peptide | “peptide drug-conjugate” NCT07190469 ↗ |
| Route | Intravenous | “given once weekly by intravenous infusion” NCT07190469 ↗ |